(19)
(11) EP 2 790 721 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.11.2018 Bulletin 2018/48

(45) Mention of the grant of the patent:
17.10.2018 Bulletin 2018/42

(21) Application number: 12829142.4

(22) Date of filing: 14.12.2012
(51) International Patent Classification (IPC): 
A61K 38/08(2006.01)
A61K 38/25(2006.01)
A61P 3/04(2006.01)
 A61K 38/12(2006.01)
G01N 33/74(2006.01)
A61P 3/10(2006.01)
(86) International application number:
PCT/IB2012/002867
(87) International publication number:
WO 2013/088241 (20.06.2013 Gazette 2013/25)

(54)

FRAGMENTS OF UNACYLATED GHRELIN FOR USE IN THE TREATMENT OF PRADER-WILLI SYNDROME

FRAGMENTE VON NICHT-ACYLIERTEM GHRELIN ZUR VERWENDUNG ZUR BEHANDLUNG VON PRADER-WILLI SYNDROM

FRAGMENTS DE GHRÉLINE NON ACYLÉE POUR L'UTILISATION DANS LE TRAITEMENT DU SYNDROME DE PRADER-WILLI

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 15.12.2011 US 201161576217 P

(43) Date of publication of application:
22.10.2014 Bulletin 2014/43

(73) Proprietor: Millendo Therapeutics SAS
69130 Ecully (FR)

(72) Inventors:
  • VAN DER LELY, Aart Jan
    NL-2662 CW Bergschenhoek (NL)
  • ABRIBAT, Thierry
    F-69110 Sainte Foy Les Lyon (FR)

(74) Representative: Be IP 
Cabinet LTL SAS Centre d'Entreprise et d'Innovation 56, Bd Niels Bohr CS 52132
69603 Villeurbanne Cedex
69603 Villeurbanne Cedex (FR)


(56) References cited: : 
EP-A1- 2 067 481
WO-A1-2008/145749
US-A1- 2008 159 991
 WO-A1-2005/039624
WO-A2-03/051389
US-A1- 2011 245 160
   
  • DELPARIGI ANGELO ET AL: "High circulating ghrelin: A potential cause for hyperphagia and obesity in Prader-Willi syndrome.", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 87, no. 12, December 2002 (2002-12), pages 5461-5464, XP055061123, ISSN: 0021-972X
  • RODRIGUEZ A ET AL: "Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes", INTERNATIONAL JOURNAL OF OBESITY, vol. 33, no. 5, May 2009 (2009-05), pages 541-552, XP002696090, ISSN: 0307-0565
  • Anonymous: "UnAcylated Ghrelin (UAG)", Alizé Pharma , 2013, XP002696091, Retrieved from the Internet: URL:http://www.alz-pharma.com/r-and-d-proj ets/unacylated-ghrelin-uag [retrieved on 2013-04-24]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).